Lung transplant recipients receiving voriconazole and skin squamous cell carcinoma risk in Australia

Med J Aust. 2014 Nov 3;201(9):543-4. doi: 10.5694/mja13.00214.

Authors

Chin Fen Neoh¹, Gregory I Snell², Bronwyn Levvey², Tom Kotsimbos², Orla Morrissey³, Monica A Slavin⁴, Kay Stewart⁵, David C M Kong⁵

Affiliations

¹ Clinical Pharmacy, Universiti Teknologi MARA, Puncak Alam, Selangor, Malaysia. david.kong@monash.edu.
² Allergy, Immunology and Respiratory Medicine, Alfred Hospital and Monash University, Melbourne, VIC, Australia.
³ Infectious Diseases, Alfred Health and Monash University, Melbourne, VIC, Australia.
⁴ Infectious Diseases and Infection Control, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
⁵ Centre for Medicine Use and Safety, Monash University, Melbourne, VIC, Australia.

PMID: 25358582
DOI: 10.5694/mja13.00214

No abstract available

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Antifungal Agents / administration & dosage
Antifungal Agents / adverse effects*
Aspergillosis / drug therapy
Australia
Bronchitis / drug therapy
Bronchitis / microbiology
Carcinoma, Squamous Cell / chemically induced*
Female
Humans
Keratosis, Actinic / chemically induced
Lung Transplantation
Middle Aged
Skin Neoplasms / chemically induced*
Tracheitis / drug therapy
Tracheitis / microbiology
Transplant Recipients*
Voriconazole / administration & dosage
Voriconazole / adverse effects*

Substances

Antifungal Agents
Voriconazole